These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 10363995)
21. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines. Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228 [TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Bendetz-Nezer S; Gazit A; Priel E Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255 [TBL] [Abstract][Full Text] [Related]
24. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467 [TBL] [Abstract][Full Text] [Related]
25. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites. Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504 [TBL] [Abstract][Full Text] [Related]
26. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578 [TBL] [Abstract][Full Text] [Related]
27. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738 [TBL] [Abstract][Full Text] [Related]
28. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Holden JA; Wall ME; Wani MC; Manikumar G Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978 [TBL] [Abstract][Full Text] [Related]
29. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010 [TBL] [Abstract][Full Text] [Related]
30. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Beidler DR; Chang JY; Zhou BS; Cheng YC Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590 [TBL] [Abstract][Full Text] [Related]
31. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Riou JF; Helissey P; Grondard L; Giorgi-Renault S Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605 [TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin. Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520 [TBL] [Abstract][Full Text] [Related]
34. Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Soret J; Gabut M; Dupon C; Kohlhagen G; Stévenin J; Pommier Y; Tazi J Cancer Res; 2003 Dec; 63(23):8203-11. PubMed ID: 14678976 [TBL] [Abstract][Full Text] [Related]
35. Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors. Ohira T; Nishio K; Kanzawa F; Ishida T; Ohe Y; Arioka H; Funayama Y; Ogasawara H; Kato H; Saijo N Int J Cancer; 1996 Sep; 67(5):702-8. PubMed ID: 8782662 [TBL] [Abstract][Full Text] [Related]
36. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Tanizawa A; Pommier Y Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509 [TBL] [Abstract][Full Text] [Related]
38. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310 [TBL] [Abstract][Full Text] [Related]
39. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Deffie AM; Batra JK; Goldenberg GJ Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693 [TBL] [Abstract][Full Text] [Related]
40. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Smith LM; Willmore E; Austin CA; Curtin NJ Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]